CLINICAL TRIALS INCLUDED PATIENTS WITH DIFFERENT MUTATIONAL AND CYTOGENETIC PROFILES 1

AZA=azacitidine; DEC=decitabine; ECOG PS=Eastern Cooperative Oncology Group Performance Status; FLT=fms-like tyrosine kinase; IDH=isocitrate dehydrogenase; LDAC=low-dose cytarabine; NPM=nucleophosmin; TP53=tumor protein p53.

*Includes 6 patients with insufficient sample for analysis in the azacitidine group, 4 in the decitabine group, and 7 in the low-dose cytarabine group.
As defined by the National Comprehensive Cancer Network® (NCCN®) risk categorization v2014.
No mitosis in 1 patient in azacitidine group (excluded favorable risk by Fluorescence in situ Hybridization [FISH] analysis).
§Patients may have had more than one comorbidity.